Table 1.
Laboratory, clinical, and demographic data of NAFLD patients and controls.
| NAFLD (n=225) | Control (n=142) | P* | |
|---|---|---|---|
| Age | 34.08±9.08 | 34.24±8.72 | 0.80 |
| Sex (Female/Male. n) | 87/138 | 61/81 | 0.41** |
| Body mass index (kg/m2) | 24.71±3.34 | 27.25±4.02 | <0.001 |
| ALT (IU/L) | 18.47±10.88 | 22.76±14.13 | 0.001 |
| AST (IU/L) | 16.99±4.60 | 18.48±5.66 | 0.015 |
| ALP (U/L) | 66.11±20.06 | 72.92±24.40 | 0.009 |
| GGT (U/L) | 18.23±12.33 | 20.72±15.76 | 0.10 |
| Total biluribin (mg/dl) | 0.59±0.53 | 0.59±0.31 | 0.17 |
| Albumin (g/dll) | 4.66±0.61 | 4.68±0.31 | 0.10 |
| Triglyceride (mg/dL) | 96.54±43.79 | 117.74±66.10 | 0.03 |
| Total cholesterol (mg/dl) | 178.90±45.13 | 185.79±41.36 | 0.03 |
| HOMA-IR | 1.71±0.77 | 2.60±1.61 | <0.001 |
| PLT (103/μL) | 234.86±62.56 | 248.56±63.44 | 0.03 |
| PCT (%) | 0.22±0.06 | 0.25±0.06 | <0.001 |
| MPV (fL) | 10.05±0.92 | 10.09±0.95 | 0.45 |
| PDW (fL) | 11.83±1.67 | 12.01±2.01 | 0.89 |
ALT – alanine aminotransferase; AST – asspartate aminotransferase; ALP – alkaline phosphatase; GGT – gamma-glutamyl transferase; PLT – platelet count; PCT – plateletcrit; MPV – mean platelet volume; PDW – platelet distribution width; HOMA-IR – homeostatic model assessment insulin resistance.
*
Mann-Whitney Test,
**
χ2 test.